Shares in Pentixapharm have been caught between a flurry of clinical milestones and the mechanics of a capital increase, with the stock trading at €1.97 — barely 5% above the €1.85 subscription price in the company’s ongoing rights offering. The Berlin-based radiopharmaceutical developer is tapping shareholders for up to €20.4 million in gross proceeds at a time when its lead diagnostic candidate, [68Ga]Ga-PentixaFor, has just secured US regulatory advantages.
The subscription period, running from July 7 to July 21, allows holders to buy four new shares for every nine they already own. Pentixapharm aims to issue up to 11,020,212 new shares, with net proceeds of approximately €19.8 million earmarked for the pivotal Phase 3 PANDA study, US market expansion, manufacturing capacity and further development of the CXCR4 platform. Main shareholder Eckert Wagniskapital, which holds nearly 36% of the equity, has committed to fully exercise its subscription rights — a vote of confidence that CEO Dirk Pleimes described in a recent interview as a clear endorsement from the company’s core backers.
FDA Fast-Track Adds to Analyst Enthusiasm
Just days after the capital increase was set in motion, the US Food and Drug Administration granted fast-track designation to PentixaFor for subtyping primary aldosteronism in adults on July 9. That followed the agency’s earlier approval of an investigational new drug application for the PANDA trial, which is expected to enroll around 270 patients and commence in the second half of 2026. The fast-track status is designed to accelerate regulatory interactions and represents a significant milestone for a firm of Pentixapharm’s size.
Analysts have taken note. NuWays AG initiated coverage on July 15 with a buy rating and a price target of €7.20, citing market potential from updated screening guidelines issued by the Endocrine Society. BankM, which is also managing the rights offering, reiterated its buy recommendation in late June with a fair value estimate of €12.61 per share on a post-money basis — well above even NuWays’ target and dramatically higher than the current trading level.
Should investors sell immediately? Or is it worth buying Pentixapharm?
Improved Cash Burn but Urgent Funding Need
Pentixapharm still generates no recurring revenue and reported a first-quarter net loss of €3.2 million, an improvement from the €4.0 million loss in the year-ago period. Cash and equivalents stood at €5.2 million as of March 31 — a figure that, without the capital injection, would have sustained operations only until early 2027. The company’s 2025 annual report, published in late March, confirmed a disciplined approach to cost management and reaffirmed the strategic priority of the CXCR4 platform.
The stock has lost 14.72% over the past month and 6.19% over the past week, reflecting the typical jitters that accompany a dilutive equity raise. Year-to-date, however, shares remain 28.59% higher. The current price of €1.97 sits roughly 12% below the 50-day moving average of €2.25 and about 38% below the 52-week high of €3.17 touched in February, but still beats the 200-day average of €1.91. The relative strength index of 38.9 points to a moderately oversold condition, while the annualized 30-day volatility of 55.79% underscores the wild swings common to clinical-stage biotechs during financing rounds.
Investors now look to the close of the subscription period on July 21 and the half-year financial report scheduled for August 6. With the main shareholder already locked in and the discount to the subscription price having narrowed sharply since the offering was announced, the market appears to be pricing in a successful conclusion to the capital increase — leaving the focus squarely on whether PentixaFor can deliver on its regulatory potential.
Ad
Pentixapharm Stock: Buy or Sell?! New Pentixapharm Analysis from July 16 delivers the answer:
The latest Pentixapharm figures speak for themselves: Urgent action needed for Pentixapharm investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 16.
Pentixapharm: Buy or sell? Read more here...
